Literature DB >> 18408477

Hypertensive nephrosclerosis.

Gary S Hill1.   

Abstract

PURPOSE OF REVIEW: Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease, however morphologic evidence on the subject is poorly understood. A perennial and vexing problem in understanding kidney hypertension is that correlations between hypertension and vascular and glomerular lesions are only moderate, in part because all of these lesions are present to a greater or lesser degree in the normotensive, aging kidney, with racial differences in severity further compounding the problem. This review looks at newer data on this topic. RECENT
FINDINGS: Recent data suggest that there are two different processes leading to glomerulosclerosis, and the combination of the two begins to explain why global correlations between hypertension and morphologic lesions are destined to remain poor. Arterial stiffening with increased pulse pressure down as far as the afferent arteriolar level likely plays an important role in the progression of glomerular lesions. Loss of renal autoregulation with glomerular hypertrophy, hyperfiltration, and focal segmental glomerulosclerosis is now recognized to contribute significantly to nephrosclerosis, particularly in the black population. Ischemic glomerulosclerosis, however, may ultimately be the most important lesion, with consequent hypoxia in the parenchyma beyond, leading to tubular atrophy and interstitial fibrosis.
SUMMARY: Hypertensive nephrosclerosis should be seen as a process with two principal modes of glomerular sclerosis, ischemic and hypertrophic, with consequent focal segmental glomerulosclerosis, contributing variably to renal failure according to race and level of hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408477     DOI: 10.1097/MNH.0b013e3282f88a1f

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  59 in total

1.  Relationship between dietary protein intake and the changes in creatinine clearance and glomerular cross-sectional area in patients with IgA nephropathy.

Authors:  Toshikazu Wada; Toshiyuki Nakao; Hiroshi Matsumoto; Tomonari Okada; Yume Nagaoka; Hideaki Iwasawa; Asako Gondo; Ami Niwata; Yoshihiko Kanno
Journal:  Clin Exp Nephrol       Date:  2014-11-16       Impact factor: 2.801

2.  Large BP-dependent and -independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers.

Authors:  Karen Griffin; Aaron Polichnowski; Hector Licea-Vargas; Maria Picken; Jianrui Long; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

Review 3.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

4.  PTEN loss defines a TGF-β-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis.

Authors:  Rongpei Lan; Hui Geng; Aaron J Polichnowski; Prajjal K Singha; Pothana Saikumar; Donald G McEwen; Karen A Griffin; Robert Koesters; Joel M Weinberg; Anil K Bidani; Wilhelm Kriz; Manjeri A Venkatachalam
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

5.  Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.

Authors:  Thana Patimarattananan; Arkom Nongnuch; Poompis Pattaranutaporn; Nattawut Unwanatham; Chuleeporn Jiarpinitnun; Nuttapong Ngamphaiboon
Journal:  Support Care Cancer       Date:  2020-06-10       Impact factor: 3.603

6.  Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Authors:  Karen A Griffin; Aaron Polichnowski; Natalia Litbarg; Maria Picken; Manjeri A Venkatachalam; Anil K Bidani
Journal:  Hypertension       Date:  2014-06-23       Impact factor: 10.190

Review 7.  What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?

Authors:  Yazan Khouri; Susan P Steigerwalt; Mershed Alsamara; Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 8.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

Review 9.  Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Authors:  Anil K Bidani; Karen A Griffin; Murray Epstein
Journal:  Am J Med       Date:  2012-08-17       Impact factor: 4.965

Review 10.  The current state of RAAS blockade in the treatment of hypertension and proteinuria.

Authors:  Rigas G Kalaitzidis; George L Bakris
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.